- Home
- ODV vs IVA Comparison
ODV vs IVA Comparison
Compare ODV & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- IVA
- Stock Information
- Founded
- ODV 2005
- IVA 2011
- Country
- ODV Canada
- IVA France
- Employees
- ODV N/A
- IVA N/A
- Industry
- ODV Precious Metals
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- IVA Health Care
- Exchange
- ODV Nasdaq
- IVA Nasdaq
- Market Cap
- ODV 866.1M
- IVA 769.0M
- IPO Year
- ODV N/A
- IVA 2020
- Fundamental
- Price
- ODV $3.07
- IVA $4.15
- Analyst Decision
- ODV
- IVA Strong Buy
- Analyst Count
- ODV 0
- IVA 7
- Target Price
- ODV N/A
- IVA $16.57
- AVG Volume (30 Days)
- ODV 2.2M
- IVA 354.0K
- Earning Date
- ODV 11-07-2025
- IVA 09-29-2025
- Dividend Yield
- ODV N/A
- IVA N/A
- EPS Growth
- ODV N/A
- IVA N/A
- EPS
- ODV N/A
- IVA N/A
- Revenue
- ODV $5,147,156.00
- IVA $19,929,536.00
- Revenue This Year
- ODV $317.30
- IVA N/A
- Revenue Next Year
- ODV $40.73
- IVA N/A
- P/E Ratio
- ODV N/A
- IVA N/A
- Revenue Growth
- ODV N/A
- IVA N/A
- 52 Week Low
- ODV $1.16
- IVA $2.11
- 52 Week High
- ODV $3.89
- IVA $7.98
- Technical
- Relative Strength Index (RSI)
- ODV 43.03
- IVA 38.70
- Support Level
- ODV $2.93
- IVA $3.79
- Resistance Level
- ODV $3.14
- IVA $7.98
- Average True Range (ATR)
- ODV 0.21
- IVA 0.75
- MACD
- ODV -0.08
- IVA -0.12
- Stochastic Oscillator
- ODV 13.44
- IVA 5.84
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.